Botulinum toxin (Botox) prior authorization — multiple indications
Customize your policy alerts
Sign up for all Alaska Medicaid policy alerts
Know when Alaska Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Form and criteria governing prior authorization requests for botulinum toxin (Botox) for Alaska Medicaid members across multiple indications (e.g., chronic migraine, spasticity, hyperhidrosis, dystonias, bladder conditions). Affects prescribers, physician-administered drug billing, and pharmacy requests to Alaska Medicaid.
No material clinical or coverage changes in this revision.
Coverage Criteria by Indication
Axillary Hyperhidrosis
Axillary Hyperhidrosis covered when ALL of the following are met
Blepharospasm
Blepharospasm covered when ALL of the following are met
Cervical Dystonia
Cervical Dystonia covered when ALL of the following are met
Chronic Migraine
Chronic Migraine covered when ALL of the following are met
Used for renewal authorization only
Chronic Sialorrhea
Chronic Sialorrhea covered when ALL of the following are met
Neurogenic Detrusor Overactivity
Neurogenic Detrusor Overactivity (NDO) covered when ALL of the following are met
Examples: oxybutynin, tolterodine, mirabegron
Overactive Bladder
Overactive Bladder covered when ALL of the following are met
Spasticity / Upper Limb Spasticity
Spasticity covered when ALL of the following are met
Form asks if spasticity is secondary to cerebral palsy; question defaults to 'No' for CP on the upper-limb specific section
Urinary Incontinence Secondary to Detrusor Overactivity
Urinary Incontinence Secondary to Detrusor Overactivity covered when ALL of the following are met
For any request to use botulinum toxin for an indication that is not an FDA‑approved use (non‑cosmetic), the form requires submission of supporting medical literature and a letter of medical necessity that documents the diagnosis and prior therapies. This additional documentation is necessary to allow clinical review of non‑FDA‑approved indications and must be attached to the prior authorization request.
Incomplete or missing additional documentation for non‑FDA‑approved indications will delay or prevent authorization; ensure the literature and letter explicitly describe the prior treatments tried and the rationale for botulinum toxin in this specific patient.
Billing and Coding Requirements
| NDC | NDC field present for pharmacy-dispensed product |
| Procedure Code | Procedure Code field required for physician providers (J-code billing) |
| ICD-10 | ICD-10 diagnosis code field required |
What Providers Must Do
Prior Authorization Required
Prior authorization is required. Complete and fax the Alaska Medicaid Botox® Prior Authorization Form to the appropriate recipient based on provider type: physician providers (office supply/J‑code billing) fax to HMS at (907) 644-8131; pharmacy providers fax to (888) 603-7696. This authorization request does not ensure eligibility or guarantee payment. Verify member Medicaid eligibility before submitting.
- Fax numbers: HMS (907) 644-8131 — physicians (J‑code); Pharmacy: (888) 603-7696
- Form available on Alaska Medicaid's Medication Prior Authorization website
Bladder/Urinary Step Therapy Requirements
Step therapy for bladder/urinary indications requires documentation of prior trials. For Neurogenic Detrusor Overactivity and Overactive Bladder, patient must have tried two different pharmacologic treatments for at least 60 days with documentation of inadequate response or a justifiable contraindication to oral antimuscarinics or oral β3‑adrenergic receptor agonists (examples: oxybutynin, tolterodine, mirabegron). For Overactive Bladder, documented behavioral therapy trials are also required and symptoms must be moderate to severe.
- Two pharmacologic trials required — duration: at least 60 days each
- Acceptable agents include oral antimuscarinics or oral β3‑adrenergic agonists (e.g., oxybutynin, tolterodine, mirabegron)
- Behavioral therapy documentation required for Overactive Bladder
- Document presence of moderate to severe urge urinary incontinence, urgency, and frequency for Overactive Bladder requests
Required Documentation and Attachments
Required documentation and attachments must accompany the prior authorization form. Physician requests must include procedure codes, date of service, and ICD‑10 diagnosis codes. Attach supporting documentation such as treatment history (dates and outcomes of prior pharmacologic therapies), behavioral therapy records when applicable, clinical notes describing symptoms, and any Letters of Medical Necessity or supporting literature.
- Procedure codes and date of service (required for physician/J‑code billing)
- ICD‑10 diagnosis code(s)
- Documentation of prior pharmacologic trials (agents used, start/stop dates, reason for discontinuation or inadequate response)
- Behavioral therapy documentation when applicable (for Overactive Bladder)
- Letters of Medical Necessity or supporting clinical literature, if applicable
Incomplete Request Denial Risk
Incomplete requests will be denied until all required information is received. Ensure all required fields on the form are completed (including prescriber and pharmacy information, drug name/NDC/strength, dosage, quantity/day supply, and attestation with prescriber signature and date).
- Complete prescriber information (name, NPI, specialty, phone, fax, group ID)
- Complete pharmacy information when pharmacy provider (pharmacy name, NPI, phone, fax, NDC, strength, dosage, quantity, day supply)
- Include attestation with prescriber signature and date
- Incomplete requests will be denied
Background
Botulinum toxin (Botox) is used across multiple neurologic and non‑neurologic conditions covered on the Alaska Medicaid prior authorization form, including spasticity, dystonias (e.g., blepharospasm, cervical dystonia), chronic migraine prophylaxis, hyperhidrosis, chronic sialorrhea, and bladder disorders such as neurogenic detrusor overactivity and overactive bladder. The form collects key clinical details—primary diagnosis, ICD‑10 code, patient age group, and indication‑specific questions—to support medical necessity determinations. For non‑FDA uses, the form additionally requires referenced literature and a letter of medical necessity that lists prior therapies and the clinical justification for treatment.
Definitions and Non-standard Uses
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.